DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs
By Craig Knox, V. Law, Timothy Jewison, Philip Liu, Son Ly, A. Frolkis, Allison Pon, Kelly Banco, Christine Mak, V. Neveu and 4 more. 2010
1,885 citations recorded by the source corpus.
DrugBank (http://www.drugbank.ca) is a richly annotated database of drug and drug target information. It contains extensive data on the nomenclature, ontology, chemistry, structure, function, action, pharmacology, pharmacokinetics, metabolism and pharmaceutical properties of both small molecule and large molecule (biotech) drugs. It also contains comprehensive information on the target diseases, proteins, genes and organisms on which these drugs act. First released in 2006, DrugBank has become widely used by pharmacists, medicinal chemists, pharmaceutical researchers, clinicians, educators and the general public. Since its last update in 2008, DrugBank has been greatly expanded through the addition of new drugs, new targets and the inclusion of more than 40 new data fields per drug entry (a 40% increase in data ‘depth’). These data field additions include illustrated drug-action pathways, drug transporter data, drug metabolite data, pharmacogenomic data, adverse drug response data, ADMET data, pharmacokinetic data, computed property data and chemical classification data. DrugBank 3.0 also offers expanded database links, improved search tools for drug–drug and food–drug interaction, new resources for querying and viewing drug pathways and hundreds of new drug entries with detailed patent, pricing and manufacturer data. These additions have been complemented by enhancements to the quality and quantity of existing data, particularly with regard to drug target, drug description and drug action data. DrugBank 3.0 represents the result of 2 years of manual annotation work aimed at making the database much more useful for a wide range of ‘omics’ (i.e. pharmacogenomic, pharmacoproteomic, pharmacometabolomic and even pharmacoeconomic) applications.
Subfields: Computational Theory and Mathematics, Molecular Biology, Pharmacology, Computational Biology & Bioinformatics, Computational Chemistry & Drug Discovery
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Computational Theory and Mathematics
- Sunghwan Kim
- Evan E. Bolton
- Stephen H. Bryant
- Jean-Louis Reymond
- Fei Wang
- Ruud Van Deursen
- Lars Juhl Jensen
- Lorenz C. Blum
In Molecular Biology
- Peer Bork
- Lars Juhl Jensen
- Sunghwan Kim
- Stephen H. Bryant
- C. von Mering
- Evan E. Bolton
- Michael Kuhn
- Damian Szklarczyk
In Pharmacology
- Fei Wang
- Patrick Aloy
- Miquel Duran-Frigola
- Michael Kuhn
- Peer Bork
- Mehmet Gönen
- Lars Juhl Jensen
- Sunghwan Kim
In Computational Biology & Bioinformatics
- Christine A. Orengo
- Peter M. Visscher
- Vikas Yadav
- Mehmet Gönen
- Janet M. Thornton
- Evan E. Bolton
- Alfonso Valencia
- John P. Overington
In Computational Chemistry & Drug Discovery
- Ruud Van Deursen
- Ruth Nussinov
- Lorenz C. Blum
- Jean-Louis Reymond
- Lars Ruddigkeit
- Jan A. Kors
- Saber Ahmad Akhondi
- Sorel Muresan
Citations in the corpus
- ChEMBL: a large-scale bioactivity database for drug discovery (2011, background): “Other resources, such as DrugBank, provide detailed annotation around the properties and mechanism of action of approved drugs (18).”
- 3D structures of membrane proteins from genomic sequencing (2012, neutral): “A survey of targets in the DrugBank database (Knox et al., 2011) for transmembrane proteins together with large families from the CAMPS (Neumann et al., 2012) yielded 18 nonredundant families with >1,000 sequences, with R 5 predicted transmembrane helices, and without a known 3D structure for any…”
- DrugBank 4.0: shedding new light on drug metabolism (2013, neutral): “well as pharmacokinetic and pharmacoeconomic information (10).”
- Linking Biochemical Pathways and Networks to Adverse Drug Reactions (2014, methodology): “The relationship between drugs and pathways was constructed by mapping protein targets extracted from DrugBank [17] to the corresponding KEGG biological pathways [18], [19] through their protein-coding gene symbols.”
- STITCH 4: integration of protein–chemical interactions with user data (2013, background): “The second channel is made up of manually curated drug–target databases: DrugBank (12), GLIDA (13), Matador (14), TTD (15) and CTD (16); and pathway databases: KEGG (17), NCI/Nature Pathway Interaction Database (18), Reactome (19) and BioCyc (20) .”
- Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects (2015, methodology): “DrugBank DDIs are extracted from drug’s package inserts (accurate but far from complete), which can be used as independent validation sources.”
- Adaptation of machine translation for multilingual information retrieval in the medical domain (2014, background): “…reviews of primary research in human health care and health policy [63], DrugBank – a bioinformatics and cheminformatics resource describing drugs [64], Gene Regulation Event Corpus (GREC) – a semantically annotated English corpus of abstracts of biomedical texts [65], the GENIA corpus of…”
- The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands (2013, background): “Of these, ChEMBL, DrugBank and Therapeutic Target Database (TTD) (30) are the closest.”